| Autor: |
A Gringeri, P Hartigan, R D'Aquila, J Yeo, L Dee, A Maeland, F Rousseau, J Darbyshire, M Flepp, T Merigan, H Chang, J Chodakewitz, C Farthing, K Stanley, G Van Weverling, L Mathiesen, R DeMasi, P Slade, H Melander, C Pettinelli, A Poppa, C Carbon, D Smith, M Seligmann, G Stingl, C Tierney, M Hughes, I Chalmers, M Foulkes, D Katzenstein, B Gazzard, L Struthers, Soriano, K Henry, J Veenstra, I Weller, S Danner, M Sande, L Deyton, E Sandstrom, M Fischl, A Phillips, D Richman, C Katlama, M Gartland, J Neaton, E King, A Collier, P Gotzsche, P Stoffels, G Rutherford, R Van der Broeck, D Allan, R Peto, J Rooney, J Ioannidis, W Duncan, F Antunes, S Schnittman, N Clendenin, J Lange, D Dixon, SK de Loes, A Babiker, E Cooper, D Hall, J Killen, P Volberding, A Hill, H McDade, A Meibohn, G Savidge, L Saravolatz, J Bruun, W Cameron, L Perrin, A Pinching, N Clumeck, M Simberkoff, P Mannucci, J Gatell, T Peto, M Heath-Chiozzi, M Salgo, G Skowron, R Van Leeuven, L Power, S Vella, J Phair, P Reiss, J Kahn, DeGruttola, D Winslow, M Myers, R Schooley, B Hirschel, S Hammer, R Leavitt, S Walker, G Collins, R Collins, J Leonard, RP Smith, D Abrams, J Mulder, J Hamilton, M Thompson, M Nessling, S Kravcik, Hiv Trialists' Collaborative Grp, D Cooper, A Breckenridge, F Goebel, J Dormont, J Weber, P Yeni, J Feinberg |
| Rok vydání: |
1999 |
| Předmět: |
|
| Zdroj: |
The Lancet. 353:2014-2025 |
| ISSN: |
0140-6736 |
| DOI: |
10.1016/s0140-6736(98)12263-8 |
| Popis: |
Summary Background To assess the effects of zidovudine, didanosine, and zalcitabine on HIV disease progression and survival, we undertook meta-analyses of individual patient data and tabular data from all randomised trials that compared these agents. Methods Individual patient data were available for 7722 participants without AIDS in the nine randomised trials of immediate versus deferred zidovudine, and 7700 participants with or without AIDS in the six trials comparing zidovudine plus didanosine, zidovudine plus zalcitabine, or zidovudine alone. The main outcomes were mortality and disease progression (new AIDS-defining event or death before any such event). Flndings In the comparison of immediate versus deferred zidovudine, during a median follow-up of 50 months, 1908 individuals progressed, of whom 1351 died. In the deferred group, 61% started antiretroviral therapy (median time to therapy 28 months, which was zidovudine monotherapy in 94%). During the first year of follow-up, immediate zidovudine halved the rate of disease progression (p Interpretation Although immediate use of zidovudine halved disease progression during the first year, this effect was not sustained, and there was no improvement in survival in the short or long term. However, the use of didanosine and, to a lesser extent, zalcitabine delayed both disease progression and death, at least when added to zidovudine. The comparative effects of these different nucleoside analogues on long-term survival should inform the choice of which to combine with other types of drug, such as protease inhibitors. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
